Panel supported by GINN - Global Institute for Novel Nicotine (GINN)
Moderator: Joel Rubenstein, GINN
Panelists:
- Shivam Bihani, Director Satyam Sun (MYNT)
- tbn, Heavens Gift
- tbn, Chemnovatic
Commercial success increasingly depends on regulatory clarity, credible evidence, and stable routes to market — yet most sector spend still flows into brand battles, incremental innovation, and defensive lobbying. This session exposes the misalignment between where money goes and where the real risks lie, offering a practical blueprint for reallocating investment toward market access, enforcement stability and long‑term category credibility.
GINN brings two high impact commercial sessions to InterTabac this year, focused squarely on the market access challenges shaping the next decade.
Panel We’re Right but We’re Losing – How the Nicotine Sector Wastes Its Own Advantage confronts the sector’s biggest strategic blind spot: despite strong science, companies continue to invest heavily in brand level competition while under funding the evidence, enforcement and regulatory infrastructure that determines commercial survival.
Location: Main Stage
Deep Dive Making Evidence Travel: A Three‑Region Blueprint for Market Access then provides the solution — a practical, three region evidence engine built to travel across FDA expectations, EU debates and LATAM’s emerging post prohibition frameworks. Together, these sessions offer manufacturers, distributors, and investors a clear roadmap for protecting access, reducing regulatory risk, and positioning for growth in the world’s most consequential markets.
Location: London | Conference Area
